Satitpitakul V, et al. - In this prospective study involving 169 participants with newly diagnosed moderate to severe meibomian gland dysfunction (MGD), researchers tested azithromycin 1.5% eyedrops vs oral doxycycline with regard to efficacy as a treatment option. They randomly allocated 85 patients to treatment with azithromycin 1.5% eyedrops twice daily for 2 days then once daily until 4 weeks and 84 patients to oral doxycycline 100 mg twice daily for 4 weeks. At baseline as well as 4 weeks later, they assessed signs and symptoms of MGD. In patients with moderate to severe MGD, a significant improvement was evident in the signs and symptoms with azithromycin 1.5% eyedrops or oral doxycycline. With regard to improved signs and symptoms of MGD and drug side effects that result in therapy discontinuation, no difference was found between azithromycin 1.5% eyedrops and oral doxycycline.